Chimeric Therapeutics Ltd has released a press release.
Chimeric Therapeutics: Half Yearly Report and Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- 1st patient treated in ADVENT-AML Phase 1b clinical trial
- Placement of Entitlement Offer Shortfall
- ADVENT-AML Phase 1B clinical trial open to enrolment
- Chimeric receives $7.36M R&D tax incentive
- Positive in vitro data for CHM 1301 CAR NK cells
Later from Chimeric Therapeutics
- Clinical milestones for 2024 & 2023 successes highlighted
- Resignation of CEO and Managing Director
- CHM CDH17 Phase 1/2 clinical trial approved for initiation
- Chimeric opens CHM CDH17 Phase 1/2 trial
- Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics